SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Tarsus Pharmaceuticals Reports Fiscal Q3 Net Loss

Tarsus Pharmaceuticals reported a fiscal 2026 third-quarter net loss attributable to shareholders, down 1,095.37% year over year, and negative basic EPS.

TARS

Related stories